Fluorescence in-situ hybridization is increasingly being used to determine HER-2/neu status in patients with breast carcinoma. The possibility that intratumoral heterogeneity of HER-2/neu gene amplification may potentially contribute to inaccurate assessment of HER-2/neu status was investigated in routine cases of invasive mammary carcinomas. From 169 representative formalin-fixed, paraffin-embedded blocks of invasive duct mammary carcinomas with grade 3 architecture, 48 cases were analyzed by fluorescence in-situ hybridization and 59 analyses were performed. Intratumoral heterogeneity for HER-2/neu gene amplification was demonstrated in only 5 (16%) of 31 cases where morphologically similar areas of a single tumor were analyzed. We conclude from this study that intratumoral heterogeneity of HER-2/neu gene amplification is a demonstrable but relatively uncommon occurrence. For invasive mammary carcinomas, the accurate assessment of HER-2/neu status by fluorescence in-situ hybridization analysis is not significantly confounded by intratumoral heterogeneity of HER-2/neu gene amplification in individual tumors.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL.Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235: 177-182.
2.
Kallioniemi OP, Kallioniemi A, Kurisu W, et al.ErbB-2 amplification in breast cancer analyzed by flourscence in situ hybridization. Proc Natl Acad Sci. 1992;89: 5321-5325.
3.
Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C.The HER-2 (c-erbB-2) oncogene is frequently amplified in the in situ carcinomas of the breast. Oncogene. 1992;7: 1027-1032.
4.
Paterson MC, Dietrich KD, Danyluk J, et al.Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991;51: 556-567.
5.
Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P.Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol. 1993;11: 1936-1942.
6.
Press MF, Pike MC, Chazin VR, et al.HER-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993;53: 4960-4970.
7.
Leitzel K, Teramoto Y, Konrad K, et al.Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol. 1995;13: 1129-1135.
8.
Carlomagno C, Perrone F, Gallo C, et al.C-erbB-2 over-expression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol. 1996;14: 2702-2708.
9.
Wright C, Nicholson S, Angus B, et al.Relationship between c-erbB-2 protein product, expression and response to endocrine therapy in advanced breast cancer. Br J Cancer. 1992;65: 118-121.
10.
Muss HB, Thor AD, Berry DA, et al.C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330: 1260-1266.
11.
Paik S, Bryant J, Park C, et al.ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90: 1361-1370.
12.
Slamon DJ, Leyland-Jones B, Shack S, et al.Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomized multinational controlled phase III trial [abstract 377]. Proc Am Soc Clin Oncol. 1998;17: 98a-98a.
13.
Cobleigh MA, Vogel CL, Tripathy D, et al.Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2- overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17: 2639-2648.
14.
Pauletti G, Godolphin W, Press MF, Slamon DJ.Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13: 63-72.
15.
Fitzgibbons PL, Page DL, Weaver D, et al.Prognostic factors in breast cancer. Arch Pathol Lab Med. 2000;124: 966-978.
16.
Thor A.HER2—a discussion of testing approaches in the USA. Ann Oncol. 2001;12(Suppl 1): S101-S107.
17.
Prati R, Apple SK, He J, et al.Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Breast J. 2005;11: 433-439.
18.
Tsuda H, Hirohashi S, Shimosato Y, et al.Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. Cancer.1990;8: 1794-1800.
19.
Berger MS, Locher GW, Saurer S, et al.Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988;48: 1238-1243.
20.
Kononen J, Bubendorf L, Kallioniemi A, et al.Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Med. 1998;4: 844-847.
21.
Mass RD, Press MF, Anderson S, et al.Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005;6: 240-246.
22.
Dybdal N, Leiberman G, Anderson S, et al.Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat. 2005;93: 3-11.
23.
Fearon ER, Vogelstein BA.A genetic model for colorectal tumorigenesis. Cell. 1990;61: 759-767.
24.
Kuukasjärvi T, Karhu R, Tanner M, et al.Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 1997;57: 1597-1604.
25.
Shen CY, Yu JC, Lo YL, et al.Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res. 2000; 60: 3884-3892.
Lengauer C, Kinzler KW, Vogelstein B.Genetic instabilities in human cancers. Nature. 1998;396: 643-649.
28.
Duesberg P, Rausch C, Rasnick D, et al.Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci USA. 1998;95: 13692-13697.
29.
Fujii H, Marsh C, Cairns P, et al.Genetic divergence in the clonal evolution of breast cancer. Cancer Res. 1996;56;1493-1497.
30.
Aubele M, Mattis A, Zitzelsberger H, et al.Intratumoral heterogeneity in breast carcinoma revealed by laser-microdissection and comparative genomic hybridization. Cancer Genet Cytogenet. 1999;110: 94-102.
31.
Sozllösi J, Balázs M, Feurstein BG, et al.ErbB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res. 1995;55: 5400-5407.
32.
Pertschuk LP, Axiotis CA, Feldman JG, et al.Marked intratumoral heterogeneity of the proto-oncogene HER-2/neu determined by three different detection systems. Breast J. 1999;5: 369-374.
33.
Glöckner S, Buurman H, Kleeberger W, et al.Marked intratumoral heterogeneity of c-myc and cyclin D1 but not of c-erbB2 amplification in breast cancer. Lab Invest. 2002;82: 1419-1426.
34.
Andersson J, Linderholm B, Bergh J, et al.HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components. Appl Immunohistochem Mol Morphol. 2004;12: 14-20.
35.
Lewis JT, Ketterling RP, Halling KC, et al.Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol. 2005;124: 273-281.
36.
Edgarton SE, Merkel D, Moore DH, et al.HER-2/neu/erb-B2 status by immunohistochemistry and FISH: clonality and progression with recurrence and metastases. Breast Cancer Res Treat. 2000;64: 55-55.
37.
Gancberg D, DiLeo A, Cardoso F, et al.Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol. 2002;13: 1036-1043.
38.
Zidan J, Dashkovsky I, Stayerman C, et al.Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer. 2005;93: 552-556.
